Skip to main content
MNPR logo

Monopar Therapeutics Inc.

MNPRNASDAQHealthcareBiotechnology

$69.27Today:- (-)1Y −10.40%

As of Oct 16, 2026 close

Market cap
$613.35M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$50.07$124.82
Volume (live)
-
Avg. volume (3M)
151.35K

Monopar Therapeutics (MNPR) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Monopar Therapeutics reported total assets of $140.72M and total liabilities of $2.89M. Shareholders' equity was $137.83M, up 150.4% from $55.04M a year earlier. Total debt stood at $154.92K against $140.40M in cash and short-term investments, a net cash position of $140.24M. That puts debt-to-equity at 0.00, compared with 0.00 a year earlier.

Monopar Therapeutics Balance Sheet Analysis

Values in millions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Monopar Therapeutics Inc. (MNPR) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Mar 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Current Assets
Cash and Cash Equivalents61.8345.8245.827.278.1920.3016.7413.216.898.98
Short-Term Investments78.5714.4014.400.004.930.000.000.000.000.00
Cash & Short-Term Investments140.4060.2160.217.2713.1220.3016.7413.216.898.98
Accounts Receivable0.000.00-0.000.000.000.000.000.000.00
Inventory0.000.00-0.000.000.000.000.000.000.00
Other Current Assets0.060.080.080.070.050.220.060.020.430.15
Total Current Assets140.4660.2960.297.3313.1720.5216.8013.237.329.13
Non-Current Assets
Property, Plant & Equipment (Net)0.250.00-0.010.060.000.000.000.000.00
Intangible Assets0.000.00-0.000.000.000.000.000.00730.65
Other Non-Current Assets0.000.00-0.000.000.000.070.120.41-729.85
Total Non-Current Assets0.250.00-0.010.060.000.070.120.410.80
Total Assets140.7260.2960.297.3513.2320.5216.8713.357.329.93
Current Liabilities
Accounts Payable2.742.252.251.763.131.581.180.720.400.31
Accrued Liabilities--3.00-------
Other Current Liabilities0.003.00-0.000.000.000.000.000.000.00
Total Current Liabilities2.745.255.251.763.131.581.180.720.400.31
Non-Current Liabilities
Long-Term Debt0.150.00-0.000.010.000.000.000.000.00
Other Non-Current Liabilities0.000.00-0.000.000.000.000.000.000.00
Total Non-Current Liabilities0.150.00-0.000.010.000.000.000.000.00
Total Liabilities2.895.255.251.763.141.581.180.720.400.31
Stockholders' Equity
Common Stock0.010.010.010.010.010.010.010.010.010.01
Retained Earnings-89.51-75.79-75.79-60.21-51.80-41.29-32.19-25.88-21.66-18.43
Accumulated Other Comprehensive Income0.130.040.04-0.010.010.00-0.01-0.010.000.00
Additional Paid-in Capital227.20130.79130.7965.7961.8760.2247.8738.5128.5728.04
Shares Outstanding6.69-6.102.982.592.52----
Total Stockholders' Equity137.8355.0455.045.5910.0918.9415.6912.636.929.62
Total Liabilities & Equity140.7260.2960.297.3513.2320.5216.8713.357.329.93

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Monopar Therapeutics Balance Sheet

How much debt does Monopar Therapeutics have?

Monopar Therapeutics had total debt of $154.92K as of Dec 31, 2025, against $140.40M in cash and short-term investments. Its debt-to-equity ratio was 0.00. Total debt was $0.00 a year earlier.

What are Monopar Therapeutics's total assets?

Monopar Therapeutics reported total assets of $140.72M as of Dec 31, 2025, up 133.4% from $60.29M a year earlier. Total liabilities were $2.89M.

What is Monopar Therapeutics's shareholders' equity?

Monopar Therapeutics's shareholders' equity was $137.83M as of Dec 31, 2025, or about $20.60 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition